Drug Approval | January 21, 2022
Medicines Patent Pool finalises 27 generic manufacturers to produce molnupiravir
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The transaction is expected to close in the first quarter of 2022
Partnering to build biosynthesis processes and a pharmaceutical production platform
A toll-free helpline to be set up to help doctors and patients
The product is expected to be available in a week’s time
The company will market it under the brand name Molflu
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
Subscribe To Our Newsletter & Stay Updated
